Inicio>>Peptides>>Ipamorelin (acetate)

Ipamorelin (acetate) (Synonyms: Aib-His-D-2-Nal-D-Phe-Lys-NH2; NNC 26-0161)

Catalog No.GC91449

Ipamorelin es un secretagogo de la hormona del crecimiento pentapéptido (GHS) y agonista del receptor GHS 1a (GHS-R1a).

Products are for research use only. Not for human use. We do not sell to patients.

Ipamorelin (acetate) Chemical Structure

Tamaño Precio Disponibilidad Cantidad
5mg
94,00 $
Disponible
10mg
122,00 $
Disponible
25mg
279,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents
Ipamorelin is a pentapeptide growth hormone secretagogue (GHS) and GHS receptor 1a (GHS-R1a) agonist.1,2 It binds to COS-7 cells expressing GHS-R1a (Ki = 63.4 nM), induces inositol-1,4,5-triphosphate (IP3) accumulation in BHK cells expressing GHS-R1a (EC50 = 46.9 nM), and induces GH release in primary rat pituitary cells (EC50 = 1.3 nM).1 Ipamorelin increases plasma levels of GH in rats and pigs (ED50s = 80 and 2.3 nmol/kg, respectively) but does not increase plasma levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin, or thyroid stimulating hormone (TSH) in pigs when administered at a dose of 420 nmol/kg.2 It increases gastric emptying in a rat model of postoperative ileus induced by laparotomy and intestinal manipulation when administered at doses of 0.014 or 0.14 µmol/kg.3 Ipamorelin (18-450 µg/animal) increases body weight and longitudinal bone growth in rats.4

Reseñas

Review for Ipamorelin (acetate)

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Ipamorelin (acetate)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.